CAMBRIDGE, Mass. — ConcertAI said it has launched Accelerated Clinical Trials, an enterprise platform that uses agentic artificial intelligence to automate and optimize the end-to-end clinical trial process, with the goal of shortening overall trial timelines and reducing development costs for sponsors and contract research organizations.
The platform, known as ACT, was unveiled at the Summit for Clinical Ops Executives 2026 in Orlando. ConcertAI said ACT integrates real-world evidence and proprietary data with advanced AI-driven workflows to help sponsors reduce clinical trial timelines by an estimated 10 to 20 months while improving study design, site selection, and real-time monitoring.
Clinical research has grown increasingly complex due to challenges such as patient recruitment, intricate trial endpoints, and fragmented data systems, often leading to costly protocol amendments. Industry research cited by the company indicates that more than three-quarters of Phase I–IV trials require amendments, with major changes frequently adding months to timelines and significant additional costs.
ACT is designed to address those challenges by creating an integrated, predictive clinical research environment. Using AI-driven probability forecasts, the platform enables teams to design and operate studies with a higher likelihood of meeting enrollment targets and achieving successful outcomes.
“Trial inefficiencies come at a high cost — both financial and for patients awaiting new therapies,” said Eron Kelly, chief executive officer of ConcertAI. “Sponsors don’t need another isolated tool; they need an end-to-end solution that identifies bottlenecks and guides next steps. With ACT, we deliver on the promise of agentic AI for life sciences, giving trial teams greater control and clear visibility throughout the entire study lifecycle.”
ACT is built on CARAai, ConcertAI’s proprietary agentic AI platform, and deploys a suite of specialized assistants and agents designed to automate key clinical trial activities. These include literature review, protocol design, competitive trial analysis, feasibility assessments, site selection, and patient matching, using advanced reasoning models.
ConcertAI said the platform has been recognized among leading AI clinical trial automation solutions for 2026 by Frost & Sullivan. In its assessment, the firm cited ConcertAI’s use of generative and agentic AI combined with proprietary real-world data to accelerate patient screening, optimize site selection, and automate clinical research workflows, particularly in oncology trials.
According to the company, ACT’s design and writing tools can reduce study design timelines by up to 50 percent and cut protocol amendments by a similar margin through AI-driven feasibility validation. Operational features are designed to streamline site selection, activation, and recruitment, reducing timelines by an estimated 25 to 50 percent through automated validation strategies.
ACT’s intelligent agents draw on both real-world and proprietary data to support faster, more accurate decision-making across the clinical trial lifecycle. The platform also supports integrations with common clinical trial systems and data sources to enable adoption within existing sponsor and CRO workflows.
